Welcome to our dedicated page for Travelers Compan SEC filings (Ticker: TRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Travelers Companies, Inc. filings document the disclosure record of a NYSE-listed property casualty insurer with common stock trading under TRV. Recent Form 8-K reports furnish quarterly results of operations, financial-condition updates, financial supplements and other material events tied to the company’s insurance operations and investment portfolio.
Travelers’ proxy materials cover board elections, executive compensation, pay-versus-performance disclosures and shareholder governance matters. Other filings record board composition changes, registered securities information and capital-structure activity, including senior note issuance and underwriting agreement disclosures.
The Travelers Companies, Inc. reported that director Laurie J. Thomsen has decided not to stand for re-election to the Board of Directors at the company’s 2026 Annual Meeting of Shareholders. She notified the company on February 3, 2026 and will serve the remainder of her term until that meeting.
The company stated that Ms. Thomsen’s decision is not due to any disagreement with management or the Board of Directors, indicating an orderly and non-contentious transition. Travelers also expressed its gratitude for her years of service on the Board.
A holder of TRV common stock has filed a Form 144 notice to sell 10,000 shares through Fidelity Brokerage Services on the NYSE around 02/06/2026. The filing lists an aggregate market value of 3,011,783.27 and total shares outstanding of 223,063,417.
The shares to be sold were acquired as common stock on 02/06/2026 following options granted on 02/04/2020, with payment made in cash. Form 144 indicates the seller represents having no undisclosed material adverse information about TRV’s current or prospective operations.
The Travelers Companies officer Paul E. Munson, SVP & Corporate Controller, reported a new grant of stock options in the company. On February 3, 2026, he was awarded 1,165 stock options with a $288.23 exercise price, expiring between February 3, 2029 and February 3, 2036. Following this grant, he directly holds 1,165 derivative securities linked to Travelers common stock.
The Travelers Companies, Inc. executive Diane Kurtzman, EVP & Chief HR Officer, reported a grant of stock options. On 02/03/2026 she acquired 6,060 stock options, each giving the right to buy common stock at an exercise price of $288.23 per share.
These options, covering 6,060 shares of common stock, are exercisable from 02/03/2029 and expire on 02/03/2036. Following this grant, she beneficially owns 6,060 derivative securities directly.
The Travelers Companies, Inc. reported an insider equity award for executive Mojgan M. Lefebvre, EVP & Chief Tech & Ops Officer. The Form 4 shows a grant of 10,651 stock options (Right to Buy) on February 3, 2026.
These options allow the purchase of Travelers common stock at an exercise price of $288.23 per share. They become exercisable on February 3, 2029 and expire on February 3, 2036. Following this transaction, Lefebvre is reported as directly owning 10,651 derivative securities in the form of these options.
Travelers Companies executive Maria Olivo, EVP, ERM & Chief Risk Officer, received a grant of stock options on February 3, 2026. The award covers 10,773 stock options with a conversion or exercise price of $288.23 per share.
These options give the right to buy Travelers common stock and become exercisable on February 3, 2029, with an expiration date of February 3, 2036. Following this transaction, Olivo directly holds 10,773 derivative securities of this type.
The Travelers Companies, Inc. executive Jeffrey P. Klenk, EVP & President, Bond & Specialty Insurance, reported an award of stock options. On February 3, 2026, he acquired 12,854 stock options with a $288.23 exercise price, each for one share of common stock.
These options become exercisable on February 3, 2029 and expire on February 3, 2036. Following this grant, Klenk beneficially owns 12,854 derivative securities directly, as reflected in the filing.
The Travelers Companies, Inc. executive Rowland David Donnay, EVP & Co-Chief Investment Officer, reported a new stock option grant. On February 3, 2026, he was awarded 7,407 stock options with a conversion or exercise price of $288.23 per share.
These options relate to Travelers common stock, are held directly, and expire on February 3, 2036. Following this grant, Donnay beneficially owns 7,407 derivative securities in the form of these stock options.
The Travelers Companies, Inc. executive Michael Frederick Klein, EVP & President, Personal Insurance, reported acquiring stock options on the company’s common stock. On February 3, 2026, he acquired 16,649 stock options (right to buy) with a conversion or exercise price of $288.23 per share.
These options become exercisable on February 3, 2029 and expire on February 3, 2036. After this transaction, Klein beneficially owned 16,649 derivative securities, held directly in his name, with the derivative securities themselves reported at a price of $0.
The Travelers Companies, Inc. reported an insider equity award for its EVP & Chief Financial Officer, Daniel S. Frey. On February 3, 2026, he was granted stock options to buy 13,026 shares of Travelers common stock.
The options have an exercise price of $288.23 per share, become exercisable on February 3, 2029, and expire on February 3, 2036. Following this grant, Frey directly holds 13,026 stock options, with no indirect ownership reported in this filing.